<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02555085</url>
  </required_header>
  <id_info>
    <org_study_id>234HV101</org_study_id>
    <secondary_id>2015-001283-18</secondary_id>
    <nct_id>NCT02555085</nct_id>
  </id_info>
  <brief_title>Single Ascending Doses of BIIB063 in Healthy Volunteers</brief_title>
  <official_title>Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety and tolerability of single
      ascending intravenous (IV) doses and a single subcutaneous (SC) dose of BIIB063 in healthy
      volunteers. The secondary objectives of the study are to estimate the PK parameters of single
      ascending IV doses of BIIB063; to estimate the PK parameters and absolute bioavailability (F)
      of a single SC dose of BIIB063; and to evaluate the immunogenicity of single ascending doses
      of BIIB063.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Clinical study terminated due to preclinical safety findings in non-human primates.
  </why_stopped>
  <start_date type="Actual">September 30, 2015</start_date>
  <completion_date type="Actual">June 1, 2016</completion_date>
  <primary_completion_date type="Actual">June 1, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant laboratory assessment abnormalities</measure>
    <time_frame>Up to week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant Vital sign abnormalities</measure>
    <time_frame>Up to week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities</measure>
    <time_frame>Up to week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant physical examination abnormalities</measure>
    <time_frame>Up to week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in antibody titers of vaccine immunization for tetanus</measure>
    <time_frame>Up to week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in antibody titers of vaccine immunization for diphtheria</measure>
    <time_frame>Up to week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in antibody titers of vaccine immunization for pneumococcus</measure>
    <time_frame>Up to week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of single-ascending IV doses of BIIB063: Maximum observed concentration (Cmax)</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of single-ascending IV doses of BIIB063: Time to reach maximum observed concentration (Tmax)</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of single-ascending IV doses of BIIB063: Terminal elimination half-life (t1/2)</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of single-ascending IV doses of BIIB063: Clearance (CL)</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of single-ascending IV doses of BIIB063: Volume of distribution at steady state (Vss)</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of a single SC dose of BIIB063: Maximum observed concentration (Cmax)</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of a single SC dose of BIIB063: Time to reach maximum observed concentration (Tmax)</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of a single SC dose of BIIB063: Terminal elimination half-life (t1/2)</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of a single SC dose of BIIB063 Apparent total body clearance (CL/F)</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of a single SC dose of BIIB063: Apparent volume of distribution during terminal elimination phase (Vz/F)</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of a single SC dose of BIIB063: Absolute Bioavailability (F)</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with positive serum anti-BIIB063 antibodies</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with positive anti-BIIB063 titers within 12 weeks after administration of BIIB063</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IV Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending IV dose or matching placebo based on body weight recorded on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending IV dose or matching placebo based on body weight recorded on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending IV dose or matching placebo based on body weight recorded on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending IV dose or matching placebo based on body weight recorded on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending IV dose or matching placebo based on body weight recorded on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending IV dose or matching placebo based on body weight recorded on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Dose 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending IV dose or matching placebo based on body weight recorded on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC dose or matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BIIB063</intervention_name>
    <description>Single ascending IV dose</description>
    <arm_group_label>IV Dose 4</arm_group_label>
    <arm_group_label>SC Dose</arm_group_label>
    <arm_group_label>IV Dose 1</arm_group_label>
    <arm_group_label>IV Dose 6</arm_group_label>
    <arm_group_label>IV Dose 7</arm_group_label>
    <arm_group_label>IV Dose 5</arm_group_label>
    <arm_group_label>IV Dose 2</arm_group_label>
    <arm_group_label>IV Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose</description>
    <arm_group_label>IV Dose 4</arm_group_label>
    <arm_group_label>SC Dose</arm_group_label>
    <arm_group_label>IV Dose 1</arm_group_label>
    <arm_group_label>IV Dose 6</arm_group_label>
    <arm_group_label>IV Dose 7</arm_group_label>
    <arm_group_label>IV Dose 5</arm_group_label>
    <arm_group_label>IV Dose 2</arm_group_label>
    <arm_group_label>IV Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  All male subjects and all female subjects of childbearing potential must practice at
             least 1 highly effective method of contraception (i.e., contraceptive measure with a
             failure rate of &lt;1% per year; estrogen-containing contraceptives are prohibited)
             during the study and be willing and able to continue contraception for 4 months after
             being dosed with study treatment. Male subjects must also be willing to refrain from
             sperm donation for at least 4 months after the last dose of study treatment. Male
             subjects must not have unprotected sexual intercourse with a female who is pregnant or
             breastfeeding during the study.

          -  Must have a body mass index between 18 and 30 kg/m2, inclusive.

          -  Must be in good health as determined by the Investigator, based on medical history,
             physical examination, and 12-lead ECG.

        Key Exclusion Criteria:

          -  History of or positive test result at screening for human immunodeficiency virus,
             hepatitis C virus antibody, or hepatitis B virus (defined as positive for hepatitis B
             surface antigen [HBsAg] or hepatitis B core antibody [HBcAb]).

          -  History of any clinically significant cardiac, endocrine, hematologic, hepatic,
             immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric,
             renal, or other major disease, as determined by the Investigator.

          -  Personal or family history of cardiovascular disease under the age of 50 years,
             inherited disorder of coagulation (e.g., Factor V Leiden, protein C or S deficiency),
             or anti-phospholipid Ab syndrome (APS).

          -  History of meningococcal vaccination or meningococcal meningitis, or history of
             hypersensitivity to single components of meningococcal vaccines (including MENVEO),
             any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine.

          -  History of tuberculosis (TB) or positive QuantiFERONÂ®-TB Gold test

          -  Personal history of thromboembolic events

          -  Treatment with any prescription or over-the-counter medication within 14 days prior to
             randomization (excluding vitamins, dietary supplements, herbal preparations,
             progestin-only birth control, and paracetamol up to 4 g/day for no more than 5
             consecutive days).

          -  Current enrollment or a plan to enroll in any interventional clinical study in which
             an investigational treatment or approved therapy for investigational use is
             administered within 3 months

          -  Current enrollment or a plan to enroll in any other drug, biologic or device clinical
             study, or treatment with an investigational drug or approved therapy for
             investigational use within 3 months

          -  Blood donation (1 unit or more) within 3 months prior to randomization.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LD2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2015</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

